ArticleIEEE transactions on medical imaging2021
Development and Evaluation of the Fourier Spectral Distortion Metric.
Article in IEEE transactions on medical imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- Exploring advanced 2D acquisitions in breast tomosynthesis: T-shaped and Pentagon geometries.Proceedings of SPIE--the International Society for Optical Engineering · 2024Article
- Line-based iterative geometric calibration method for a tomosynthesis system.Medical physics · 2024Article
- Non-Isocentric Geometry for Next-Generation Tomosynthesis With Super-Resolution.IEEE transactions on medical imaging · 2024Article
- Next generation tomosynthesis image acquisition optimization for dedicated PET-DBT attenuation corrections.Proceedings of SPIE--the International Society for Optical Engineering · 2021Article
- Pre-clinical evaluation and optimization of image quality for a Next Generation Tomosynthesis prototype.Proceedings of SPIE--the International Society for Optical EngineeringArticle
- Achieving Isotropic Super-Resolution with a Non-Isocentric Acquisition Geometry in a Next-Generation Tomosynthesis System.Proceedings of SPIE--the International Society for Optical EngineeringArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
A spatial resolution metric is presented for tomosynthesis. The Fourier spectral distortion metric (FSD) was developed to evaluate specific resolution properties of different imaging techniques for digital tomosynthesis using a star pattern image to plot modulation in the frequency domain. The FSD samples the spatial resolution of a star-pattern image tangentially over an acute angle and for a range of spatial frequencies in a 2D image or 3D image reconstruction slice. The FSD graph portrays all frequencies present in a star pattern quadrant. In addition to the fundamental input frequency of the star pattern, the FSD graph shows spectral leakage, square wave harmonics, and residual noise. The contrast transfer function (CTF) is obtained using the FSD graph. The CTF is analogous to the modulation transfer function (MTF), but it is not normalized to unity at zero spatial frequency. Unlike the MTF, this metric separates the fundamental input-frequency from the other signals in the Fourier domain. This metric helps determine optimal image reconstruction parameters, the in-plane limit of spatial resolution with respect to aliased signals, and a threshold criterion for an image to support super resolution and reduce aliasing artifacts. Various sampling parameters were evaluated to optimize this metric and ascertain measurement accuracy. The FSD adequately compares resolution properties of 2D images and 3D image reconstruction slices for various x ray imaging modes without suppressing aliased signals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.